18 Health System CEOs, 1,300+ Caregivers Implore Congress to Support Biden Gun Violence Plan

With deaths and injuries from shootings spiking nationwide, 18 of the nation’s most prominent health system CEOs and more than 1,300 health care professionals across America have sent an urgent request to Congressional leaders, asking them to support President Biden’s plan to invest $5 billion in hospital- and community-based gun violence intervention programs. In a rare call to action by health care leaders whose hospitals were inundated by victims of COVID-19, the health professionals warned that gun violence poses an equally urgent public health crisis that requires the same vigorous response. Combined, the CEOs run health systems that employ over 700,000 health care professionals nationwide.

”From trauma bays to operating rooms, health care professionals see the breadth and severity of the gun violence crisis in stark terms,” said Michael Dowling, president & CEO of Northwell Health in New York. “We have a responsibility to respond and protect the health of our patients and communities — but to do that most effectively, we need Congress to help us do our jobs. Addressing gun violence isn’t a Republican issue or Democratic issue — it’s a public health issue.”

The plea from America’s health care CEOs and caretakers — which was sent to Senate Majority Leader Charles Schumer, House Speaker Nancy Pelosi, Senate Minority Leader Mitch McConnell, and House Minority Leader Kevin McCarthy — was the result of a grassroots effort led by Mr. Dowling, Chethan Sathya, MD, the director of Northwell’s Center for Gun Violence Prevention, and Joseph Sakran, MD, a gun violence survivor, trauma surgeon and director of emergency general surgery at The Johns Hopkins Hospital in Baltimore. Through their advocacy, they helped galvanize health leaders across America to urge Congressional support of hospital- and community-based violence intervention programs (HVIPs). These programs enable health care professionals to screen non-fatal gunshot patients to identify those at greatest risk for re-injury and connect them with support services, including trauma-informed care, job training, and housing.

Many health systems are already taking steps to implement intervention programs. In some cities, as many as45% of patients with a history of violent injury return with another injury within the next five years. But programs dedicated to intervening at this critical juncture have a proven track record of success. A HVIP in Baltimore, for example, saw the injury recidivism rate for patients fall to as low as 5%. Utilizing a $1.2 million grant from the National Institutes of Health, Northwell Health is screening patients for gun violence risk. Gun owners are counseled about safe firearms practices and high-risk individuals are connected to support services,

“Gun violence is a pressing public health crisis and racial equity issue that requires a public health response,” said Fatimah Loren Dreier, executive director of the Health Alliance for Violence Intervention. “That’s why investing in hospital- and community-based interventions that address the underlying drivers of violence is so important and impactful.”

The funding request comes as gun violence in America reaches crisis levels. Last year, the U.S. experienced a record 43,559 firearms-related deaths and more than 39,000 additional injuries — and the nation is on pace this year to surpass that grim milestone. That’s more than the number of Americans who die from high blood pressure, malnutrition, HIV, Parkinson’s disease, and viral hepatitis. Like many of those diseases, gun violence disproportionately impacts communities of color. For example, gun violence is the leading cause of death for young Black men in America – accounting for more deaths than the next nine leading causes combined.

Many of the signers of the letter to Congressional leaders are already participants in a “Learning Collaborative” established this spring by Northwell’s Center for Gun Violence Prevention to share and develop best practices for preventing firearm injury and death.

 

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”